Can a weekly obesity pill move beyond GLP-1? Verdiva Bio puts oral amylin candidate VRB-103 into human testing
Verdiva Bio has begun Phase 1 testing of weekly oral amylin candidate VRB-103. See what the trial can prove and what remains uncertain.
Pharma & Biotech
Pharma & Biotech
Can Sciwind Biosciences’ ecnoglutide challenge conventional GLP-1 drugs in the expanding obesity market?
China approves Sciwind Biosciences’ ecnoglutide for weight management. Discover what the biased GLP-1 mechanism could change in the obesity drug race.